Google
IMNN — IMUNON INC (Healthcare >> Biotechnology)
IMNN FAQ
What is IMNN's ROE?
IMUNON INC reports a Return on Equity (ROE) of -435.81%.
What is IMNN's dividend yield?
IMUNON INC offers a dividend yield of 0.00%.
What is IMNN's Deepscope Quality Score?
Deepscope rates IMNN's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMNN?
Deepscope's AI Timing Score for IMNN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMNN belong to?
IMUNON INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.02
Price
-0.01
(-0.49%)
Day Change
|
|
|---|
IMNN, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.02 |
| PBV / Sector |
2.54 / 4.91
|
| Earning Per Share | -3.47 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:00 |
| Symbol | IMNN |
| Name | IMUNON INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.53 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 997 Lenox Drive, Lawrenceville, NJ, United States, 08648
Phone: 609 896 9100
Website: https://imunon.com
Sector: Healthcare >> Biotechnology
Description: Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
